1561. Rhinovirus Infection among Patients with Hematologic Malignancy
Session: Poster Abstract Session: Infections in the Immunocompromised Hosts
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
  • Rhinovirus 9.24. final.pdf (433.3 kB)
  • Background:

    Novel Rhinovirus (RV) research has elevated the role of the virus as a significant contributor to respiratory complications in immunocompromised (IC) patients. Although RV has been implicated to cause morbidity and mortality in IC patients, its role has been difficult to characterize due to a limited availability of conventional diagnostics. Recent developments in PCR techniques have enabled better detection of RV and thus a means to better study its impact on IC patients. 


    This was a retrospective chart review of 81 bone marrow transplant (BMT) and HM patients from Moffitt Cancer Center in Tampa, FL. The patients were identified based on the presence of hematologic malignancies(HM), with or without a history of BMT, and a positive nasopharyngeal swab PCR for RV with symptomatic infection.


    Among patients with RV infection, 97.5% (79/81) had a mild illness. Of those patients, all had resolution of symptoms by 31 days after the onset of symptoms. 17.2% (14/81) had evidence of pneumonia on imaging studies. 55.5% (45/81) had evidence of lymphopenia versus only 28.3% (23/81) with evidence of neutropenia. The overall mortality was 2.4% (2/81) with both patients having evidence of co-infection with another pathogen at the time.  The most common co-pathogens were CMV(5 cases),  metapneumovirus(2 cases), respiratory syncytial virus(1 case), adenovirus (1 case), coronavirus(1case), aspergillus(2 cases), Mycobacterium avium-intracellulare(1 case), Pseudomonas aeruginosa(1 case). 


    Our study found that the overall mortality associated with RV was low but that co-infection was associated with mortality. Further studies are needed to determine the role of RV persistence, clearance, and its contribution to the pathogenesis of co-infection and post-viral complications in this vulnerable population.

    Mitsuya Katayama, M.D.1, Joseph Halliday, D.O.1, Dat Nguyen1 and John Greene, M.D., F.A.C.P.1,2, (1)University of South Florida College of Medicine, Tampa, FL, (2)Moffitt Cancer Center, Tampa, FL


    M. Katayama, None

    J. Halliday, None

    D. Nguyen, None

    J. Greene, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.